Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy
研究概览
简要总结
The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be eligible for, and have consented for low level light therapy
- •Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
- •Ability to give informed consent.
- •Age more or equals to 21 years old.
排除标准
- •Patients who are unable to or decline to give consent.
- •Age less than 21 years old.
- •Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.
- •Patients not suitable for low level lighttherapy:
- •Fitted with pacemakers, metal, electrical, acoustic prosthetics
- •Epilepsy, cardiac rhythm or frequency disorders
- •Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months
- •Uncontrolled hypertension or severe diabetes
- •Open wounds on eyelid or skin
- •Evolving cancer or hepatitis
- •Blood anticoagulant or coagulation defect
研究组 & 干预措施
Patients undergoing low level light therapy
结局指标
主要结局
Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy
时间窗: Baseline visit and Post Baseline visit 3 months (+3 weeks).
Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT
次要结局
未报告次要终点
研究者
Louis Tong
Clinician-Scientist, Senior Consultant
Singapore National Eye Centre